Observational studies: a valuable source for data on the true value of RA therapies. - Wikidata - awgldk - TriplyDB

Observational studies: a valuable source for data on the true value of RA therapies.

Observational studies: a valuable source for data on the true value of RA therapies.

http://www.wikidata.org/entity/Q33779130

about

Effectiveness of triple therapy with direct-acting antivirals for hepatitis C genotype 1 infection: application of propensity score matching in a national HCV treatment registry.Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice.

P2860

Q33576871-F047E38F-5A15-4098-84E1-7B2B2ED937A6 Q36830635-1CAB2F56-FFD4-431A-B9CA-0402B1FFE0A0 Q48517263-36F89C23-0315-465A-8B3F-AFAF2791459E

P2860

Observational studies: a valuable source for data on the true value of RA therapies.

http://www.wikidata.org/entity/Q33779130

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Observational studies: a valuable source for data on the true value of RA therapies.

@ast

Observational studies: a valuable source for data on the true value of RA therapies.

@en

type

label

Observational studies: a valuable source for data on the true value of RA therapies.

@ast

Observational studies: a valuable source for data on the true value of RA therapies.

@en

prefLabel

Observational studies: a valuable source for data on the true value of RA therapies.

@ast

Observational studies: a valuable source for data on the true value of RA therapies.

@en

P1433

Q33779130-B9C3D07D-51AD-4BC0-860D-05C60013BE6D

P1476

Q33779130-3C79F8D4-D4CF-478B-96AF-6D444C94BE6E

P2093

Q33779130-BAF0CA82-B363-48C2-A809-BAAEE56CD32C

P2860

Q33779130-0C2C9F49-E3C6-4C44-B891-02B6D610D2AD

Q33779130-287E88B1-3306-41D4-A212-88F1AF2824DE

Q33779130-35A3CC86-3AC2-4E7E-BD34-C9397B042311

Q33779130-56E38701-C269-4158-AD38-0EC7CF0DACB4

Q33779130-6E5E7A98-FD06-4916-A4DD-5933581EB81E

Q33779130-708D0FF7-D7FC-403F-907E-C35B1B94DB6F

Q33779130-7126500E-73C7-44C1-B51D-2E82E1DC1765

Q33779130-72F6B206-B019-4A60-8BC9-1A04423DB65A

Q33779130-7D244396-1731-40C8-B104-8BE2959102BC

Q33779130-8F77A231-AA89-471B-84AC-25A03FC64BEF

P304

Q33779130-D4F589CB-A1FF-44CA-AF7C-EE1FE66052BD

P31

Q33779130-73E47749-44D2-457E-BEFB-1D948D656B23

Q33779130-c6d4ebc8-17a6-4441-bf47-3ac9e1345bb1

P356

Q33779130-9C30AAF6-086D-4044-B2CC-D9C630CE0F8E

P478

Q33779130-765E1DD2-61C2-46FF-8715-0731D68136FE

P50

Q33779130-4A1C9CCD-A548-474B-B1C9-AFDBB8330162

P577

Q33779130-5FB657BD-D5E9-494D-BB7E-16FEF8AA7C72

P698

Q33779130-F6124ABE-100A-4201-A3E2-383C1E2D34A2

P356

S10067-010-1636-7

P1433

Clinical Rheumatology

P1476

Observational studies: a valuable source for data on the true value of RA therapies.

@en

P2093

Johan L Severens

http://www.w3.org/2001/XMLSchema#string

P2860

Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.

Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry).

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

P304

S19-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10067-010-1636-7

http://www.w3.org/2001/XMLSchema#string

P478

30 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P50

Ronald van Vollenhoven

P577

2010-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21181221

http://www.w3.org/2001/XMLSchema#string